Search for: rheumatoid arthritis methotrexate autoimmune disease biomarker gene expression GWAS HLA genes non-HLA genes
| ID | PMID | Title | PublicationDate | abstract |
|---|---|---|---|---|
| 4060801 | [Ischemic colitis in Reiter syndrome]. | 1985 Feb | Involvement of visceral organs is a recognized condition of Reiter's Syndrome. To our knowledge, however, involvement of the colon, as it is seen in other rheumatoid-like processes mostly caused by vasculitis, has not been described before. We present the case of a patient with incomplete Reiter's Syndrome with arthritis, circinate balanitis and psoriasilike lesions of skin and nails who developed ischemic colitis. Angiographic features point to vasculitis as a potential cause, although this could not be proved. It is possible but, as we believe, unlikely that simultaneously administered steroid treatment may have contributed to the development of the lesions. | |
| 6412723 | Genetic control of rheumatoid factor production in the mouse. Role of genes linked to the | 1983 Sep | The influence of Igh-1 and H-2 linked genes on the production of IgG2a-specific rheumatoid factors (RF) by 129/Sv mice was examined. Heterozygous animals carrying the 129 alleles, H-2b and Igh-1a, and either H-2k, H-2a, or Igh-1b (but not Igh-1d or Igh-1e) had considerably reduced RF levels. In contrast, Igh-1b linked genes failed to suppress RF production by MRL/MpJ-lpr mice. This lack of suppression was linked to the lymphoproliferation trait characteristic of these animals. | |
| 7440725 | Antiglycolipid autoantibody detected in the sera from systemic lupus erythematosus patient | 1980 Dec | A high incidence of autoantibody against the neutral glycolipid "asialo GM1" was observed in sera from patients with systemic lupus erythematosus (SLE) with neurological disorders, using an immunoflocculation test. The sera from 14 out of 17 cases of SLE with neurological disorders showed antibody activity against asialo GM1 but not against the following glycolipids: asialo GM2 GM1, and galactocerebroside. In another 87 cases of SLE without any history of seizures, as well as 61 cases of other autoimmune diseases (rheumatoid arthritis, progressive systemic sclerosis, mixed connective tissue disease, etc.) and 20 cases of various neurological diseases (epilepsy, multiple sclerosis, etc.), no antibody could be detected. In general, the antibody titer was high several months, even years, before and/or after the seizure, though the titer was low at the time that patients showed definite neurological symptoms. Immunochemical characterization with Sephadex G-200 chromatogrphy and protein A-Sepharose CL-4B affinity column indicated that the antiasialo GM1 was probably an autoantibody belonging to the immunoglobulin G class. The above results suggest that this newly found autoantibody plays a role in the pathogenesis of neurological disorders accompanying SLE. | |
| 4017310 | Antibodies to cardiac conducting tissue in progressive systemic sclerosis. | 1985 Apr | Cardiac conducting tissue antibodies (CCTA) were detected, using indirect immunofluorescence, in 8 (25%) out of 32 sera from patients with progressive systemic sclerosis (PSS) and in 39 (35%) out of 110 with rheumatoid arthritis (RA). Conduction abnormalities, namely right bundle branch block, were present in 19 (59%) of the PSS patients and in 37 (32%) of the RA cases. No significant correlation was found between the prevalence of CCTA and conduction abnormalities in PSS patients, while this was present in RA patients (p less than 0.001). CCTA were always negative in 18 patients with systemic lupus erythematosus and were found in one out of 8 cases with Sjögren's syndrome, also positive for rheumatoid factor without clinical RA. These data suggest that CCTA are evoked when involvement of cardiac conducting tissue (as in RA) or working myocardium (as in PSS) is present. Whether CCTA should be mainly regarded as an expression of the immunological derangement underlying these pathological conditions or whether they are secondary to myocardial tissue damage, must still be clarified. | |
| 322037 | [Levamisole, stimulant of the immune system in animal and man (author's transl)]. | 1977 Jan | Levamisole, a drug initially used for its antihelminthic properties has been recently emphasized when Renoux proved its immunostimulating effects in mice en 1971. Since this date, numerous publications concerned the immunological activity of this drug in animals and men. These come to the conclusion that levamisole is capable of restoring cellular immunity as demonstrated by clinical and biological tests (restoration of delayed skin hypersensitivity, increase of the percentage of rosette forming cells and PHA transformed cells). In men, its seems possible to confirm the therapeutic activity of this molecule in a wide range of disease with suspected or proven immunological deficiency. In different forms of cancer, when most of the tumor volume is first reduced, levamisole therapy significantly increases both remission and survival. In auto immune diseases (rheumatoid arthritis, systemic lupus erythematosus), levamisole seems to be strikingly effective. In viral infections (zoster, recurrent herpes, aphthous stomatitis) levamisole is able to reduce the duration of outbreaks and prolong the disease free interval. Finally, encouraging results have been obtained in patients with lepromatous leprosis. Other conditions, where an immunological deficiency is suspected are under study with levamisole therapy. This low molecular weight synthetic drug is perhaps the first pharmacological agent which acts on the host defense mechanisms. | |
| 526125 | Extra-articular processes in osteoarthropathia psoriatica. | 1979 Oct | 1. Osteo-articular manifestations in the context of osteoarthropathia psoriatica are characterized by two completely different processes. 2. The intra-capsular synovitis does not differ qualitatively in respect to twelve morphological characteristics from that of rheumatoid arthritis. Only RA-necroses never occur in psoriatic arthritis. 3. The extra-capsular process occurs at the compact as well as the spongy bone of the phalanges. The process shows no sign of a previous or current inflammation or of osteoclast activity. It is characterized by a focal loss of proteoglycan interstitial substance and the exposure of the collagen fiber matrix. 4. This focal proteoglycan loss sets off a process which takes place in four phases: a) Loss of proteoglycan interstitial substance and exposure of the preserved collagen fiber matrix of the bone. b) Deposition of osteoblast chains to the area of the exposed bone and formation of osteoid within the old collagen fiber framework. c) Remodelling of bone defects through filling in of the preserved collagen fiber matrix with newly formed woven bone. d) Reconstruction of this bone into lamellar bone, whereby excessive bone structure ("protuberances") may develop, but final balance of bone remains negative. 5. The described process, which begins with proteoglycan loss, is considered as an enzymatic disturbance, which is causatively connected to the skin process. Scintigraphic examinations indicate that this extra-articular process in the bone, in contrast to arthritis, in part clinically unobserved, is to a high percentage connected to the skin process and is, therefore, probably an integral part of psoriatic disease. | |
| 6288942 | The effect of auranofin and sodium aurothiomalate on peripheral blood monocytes. | 1982 May | The effect of oral and parenteral gold preparations on the functional capacity of human peripheral blood monocytes was studied in various in vitro systems. Both agents were capable of inhibiting monocyte chemotaxis, expression of Fc and C3 receptor sites and to a lesser extent the reduction of nitroblue tetrazolium dye. No difference was observed in the effect of oral or parenteral gold on normal and rheumatoid monocytes. The inhibition of monocyte function by gold salts was associated with an increase in intracellular cyclic AMP levels. Our data suggests that the beneficial effect of gold salts in rheumatoid arthritis may result from its action on the functional activities of the monocyte-macrophage system. | |
| 104928 | Effect of auranofin, a new antiarthritic agent, on immune complex-induced release of lysos | 1977 Jun | Auranofin, an oral chrysotherapeutic agent effective in the treatment of rheumatoid arthritis (RA), was found to be a potent, noncytotoxic inhibitor of IgG-RF immune complex-induced lysosomal enzyme release (LER) from human leukocytes. At a concentration of 1 microg Au/ml (5 microM), auranofin produced a marked reduction in beta-glucuronidase (100%), acid phosphatase (88%), and lysozyme (72%) release. In contrast, gold sodium thiosulfate (GST, an injectable gold compound) had no inhibitory activity on LER at equivalent gold concentrations (i.e., 1 microg Au/ml) and only modest activity (less than 36% inhibition) at concentrations as high as 40 microg Au/ml. The 50% inhibitory dose (LD50) of auranofin on LER was calculated to be 3-4 microM (0.6-0.8 microg Au/ml). Blood gold levels in auranofin-treated RA patients were found to be within the range required for in vitro inhibition of LER, and correlated with decreases in IgG, RF titers, and IgG-RF immune-complex formation in vitro. These results suggest that the therapeutic action of auranofin may be caused, at least in part, by inhibition of LER and/or decreases in immune-complex formation. | |
| 6286236 | Collagenase production by cloned populations of rabbit synovial fibroblasts. | 1981 Sep | Monolayers of rabbit synovial fibroblasts treated experimentally with phorbol myristate acetate produce large amounts of collagenase and prostaglandin E2 and have been a suitable experimental model for the proliferative/destructive lesion of rheumatoid arthritis. We used X-irradiation to prolong the in vitro lifespan of these cells so that cloned populations could be studied. By a number of criteria, X-irradiation did not alter the cells to make them unrepresentative of synovial fibroblasts. With limiting dilution techniques, we simultaneously isolated three clones. These clones were shown to have different growth rates and to produce different amounts of collagenase and prostaglandin E2. Rates of protein synthesis, measured by incorporation of 3H-leucine, were similar for all three clones. Our data support the concept that particular populations of synovial cells may contribute selectively to the joint destruction seen in rheumatoid disease. | |
| 18748470 | The relationship between genetics and environment in the pathogenesis of rheumatic disease | 1979 Sep | Major developments have taken place to further our understanding of the relationship between genetics and the environment in the pathogenesis of rheumatic disorders. The association between HLA markers and human disease is becoming clearer. For instance, HLA-DRW4 frequently occurs in patients with rheumatoid disease, and penicillamine and gold toxicity are seen most often in patients with HLA-DRW2 or DRW3. Antisera to B alloantigens help define the genetic differences between systemic lupus erythematosus and rheumatoid arthritis. As yet, the most dramatic link is that between HLA-B27 and primary ankylosing spondylitis. This same antigen is related, to varying degrees, with other members of the seronegative spondylarthritides and there is strong evidence that this association is related to HLA-B27, itself, rather than an associated disease gene. Nevertheless, some data refute a single gene theory. We are just beginning to learn more about interactions between different genes on the sixth chromosome and genes on other chromosomes.The sex ratio of the spondylarthritides is now better defined. Sacroiliitis may have a comparable sex distribution although females have more peripheral joint disease and males have greater spinal involvement. Unfortunately, the explanation for these differences remains elusive.The specific infective agents related to the development of rheumatic disorders are becoming clarified. Chlamydia, Salmonella, Yersinia and Shigella flexneri types 1b and 2a are arthritogenic, while Shigella sonnei appears not to cause disease. Although the Reiter syndrome is now considered a chronic disease, the reason for remissions and relapses remains unclear. | |
| 6283302 | Neurologic complications of primary Sjögren's syndrome. | 1982 Jul | Although peripheral nervous system disease has been well documented in Sjögren's syndrome (SS), central nervous system (CNS) involvement is considered distinctly uncommon. Sixteen patients with primary SS and CNS disorders not attributable to other causes were the subjects of this study. Cerebral manifestations, both focal and diffuse, as well as spinal cord disease, were observed. Peripheral vasculitis occurred in 12 patients (75%), 83% of whom had anti-Ro(SSA) antibodies. The high proportion of patients with concomitant peripheral vasculitis, and the observed association with antibodies to the Ro(SSA) antigen system which, in other studies, has been linked to vasculitis in SS, suggest that an immune vasculopathy may play a role in the pathogenesis of the CNS disease of SS. | |
| 7126773 | [Systemic scleroderma : salivary immunoglobulins and the Gougerot-Sjögren syndrome]. | 1982 Jan | The concentrations of immunoglobulins (Ig) A, G and M were measured in saliva using an electro-immunodiffusion technique at pH 5 with carbamylation of the antisera. Thirty-one controls and 20 patients with generalised scleroderma (10 with and 10 without Sjögren's syndrome) were studied. The three classes of immunoglobulins were in normal saliva. A concentration of IgG greater than 55 mg/l in whole saliva was associated with Sjörgren's syndrome. This is the consequence of the reduction of the rate of saliva production, as well as an increased local synthesis of IgG. The measurement of IgG in unconcentrated saliva could be useful in the detection of Sjögren's syndrome. | |
| 6970963 | [Renal histology in 44 patients with specific antibodies of soluble nuclear antigens]. | 1980 Oct | The authors studied the correlations between renal histology and specific antinuclear antibodies of soluble nuclear antigens (anti-Sm, anti-RNP, anti-protein) in 44 patients with such auto-antibodies. They were mostly patients with lupus erythematosus (35/44), more rarely mixed collagen disease or Sjögren's disease. The presence of any one of the specific antibodies of nuclear antigens is not associated with any special renal prognosis; thus the presence of anti-RNP does not mean that there are no histological renal lesions. The renal prognosis depends in fact on the presence of anti-ADN native antibodies. Among the other laboratory parameters (rheumatoid factors, complement levels, cryoglobulinemia) only hypocomplementemia seems to be associated with a poor renal prognosis, the presence of rheumatoid factor has perhaps a protective role. | |
| 979878 | [Sjögren's syndrome with pulmonary fibrosis. A case report (author's transl)]. | 1976 Oct 15 | The case is pointing to two remarkable facts: 1. Sjögren's syndrome may also be proceeding--without demonstrating any inflammatory rheumatic symptoms--with an isolated pulmonary fibrosis, as it had been evident in another case mentioned. 2. In certain circumstances, it may be considerably difficult to differentiate, with reliable certainty, the morphological changes in the salivary gland from those of a malignant lymphoma. Besides, also in literature there are reports concerning malignant degeneration turning into malignant lymphomata [1,8] in cases of Sjögren's syndrome. | |
| 6603221 | Antibodies to Sm and RNP. Prognosticators of disease involvement. | 1983 Jul | The charts of 150 consecutive patients found to have antibodies to Sm, ribonucleoprotein (RNP), or both were examined to determine these antibodies' possible associations with certain clinical conditions as well as their diagnostic specificities. Patients with anti-Sm were more likely to have renal disease and antibodies to double-stranded DNA, single-stranded DNA, and nuclear protein than were patients with anti-RNP. No clinical associations were found for anti-RNP. Although most of the patients with antibodies to Sm, RNP, or both had systemic lupus erythematosus, some had other diagnoses, including cutaneous lupus, drug-induced lupus, rheumatoid arthritis, juvenile arthritis, mixed connective tissue disease, Raynaud's disease, progressive systemic sclerosis, miscellaneous rheumatic and nonrheumatic diseases, and undifferentiated connective tissue disease syndromes. These findings suggest that these antibodies may be associated with some diseases, but are not disease-specific. | |
| 7019805 | Treatment of xerostomia: a double-blind trial in 108 patients with Sjögren's syndrome. | 1981 Jun | The first-ever controlled study of a therapeutic modality for xerostomia is reported. A recently described formulation for saliva substitute (SS) has been tested against a glycerine mouthwash as a control saliva substitute (placebo) in a double-blind clinical trial in 108 patients with varying grades of xerostomia of Sjögren's syndrome. The results indicate that SS offered significant relief of nocturnal oral discomfort (p less than 0.02) and more patients reported "excellent" improvement (p less than 0.01) on a five-point graded response. In all other respects, the SS was not significantly better than the placebo. Significant adverse effects were not reported. It is suggested that any such current and future therapeutic modalities for Sjögren's syndrome be subjected to similar critical appraisal of their worth. | |
| 7443501 | [Diffuse interstitial pneumopathy associated with limited Sjögren's syndrome (author's tr | 1980 Nov 29 | Diffuse interstitial pneumopathy was found to be associated with limited Sjögren's syndrome (i.e. without connective tissue involvement) in 5 women aged from 48 to 83 years. The respiratory symptoms (dyspnoea, unproductive cough and crepitations) appeared before the dry-eye-and-mouth syndrome was diagnosed in two patients and several years afterwards in three. Respiratory function studies showed a mixed restrictive and obstructive syndrome, perturbed Co transfer and increased total expiratory airways resistance. These changes reflected the underlying pathology, as revealed by bronchial and lung biopsies, which consisted of lymphocyte and plasmocyte infiltration and fibrosis of the interalveolar septa, peribronchial spaces and bronchial glands. Abnormal respiratory function tests in 5 other patients without any respiratory symptom suggest that subclinical and subradiological lesions of the lungs and bronchi are not uncommon in Sjögren's syndrome. | |
| 1058430 | Felty's syndrome. | 1975 Sep | The clinical and pathologic findings of Felty's syndrome are discussed. A case is presented which demonstrates the nonspecific inflammatory oral lesions commonly seen with this syndrome. The role of the dentist in relating these nonspecific lesions to the basic disease process is emphasized. | |
| 4001650 | [Dermatopolymyositis and pulmonary fibrosis associated with Gougerot-Sjogren syndrome. Stu | 1985 Mar | 3 new cases of dermatomyositis associated with diffuse interstitial pulmonary fibrosis and, more exceptionally, with Sjögren's syndrome are reported. The pulmonary fibrosis observed in patients with dermatomyositis differs from that found in other connective tissue diseases in that it follows a more acute course and may respond to corticosteroids. Thus, in 2 of these patients treated with corticosteroids (combined in 1 case with cyclophosphamide) the high percentage of lymphocytes and polymorphonuclears in the broncho-alveolar lavage fluid, which reflects alveolitis activity, was reduced and the pulmonary fibrosis was cured in one patient and stabilized in the other. | |
| 6675866 | The clinical picture of benign lympho-epithelial lesion. | 1983 Dec | The histopathological diagnosis 'benign lympho-epithelial lesion' characterizes the major salivary gland disease in Sjögren's syndrome. It is not known if all cases with microscopically diagnosed benign lympho-epithelial lesion are variants of Sjögren's syndrome. The present clinical investigation showed that in 19 patients with the microscopical diagnosis of lympho-epithelial lesion, 84% fulfilled all criteria of Sjögren's syndrome. The rheumatoid factor and/or antinuclear factor was found in 84% and M-component was present in 16%. Sialography revealed sialectasis in all parotid glands. Salivary gland enlargement was found in 79%, and keratoconjunctivitis sicca in 89% of the patients. Systemic disease was found in 32%. The disease in the 2 patients with M-component took a malignant course, culminating in immunoblastic sarcoma and myelomatosis. The clinical diagnosis 'autoimmune sialadenitis' is proposed for the oral and salivary gland component is Sjögren's syndrome. |